| Company | Value | Change | %Change |
|---|
Glenmark in an exchange filing said that the first clinical data from Phase 1 study of Trispecific TREAT Antibody, ISB 2001, showed a high overall response rate (ORR) with durable responses and favourable safety profile in patients with heavily pretreated Multiple Myeloma.
The initial results from 20 patients treated as of October 1, 2024, demonstrated an overall response rate of 75% across all doses tested. The doses ranged from 0.005 to 1.2 mg per kg. This came with a stringent complete remission (sCR) and complete remission (CR)rate of 20%.
Data suggests that the ISB 2001 could compare favourably with approved bispecific options, Glenmark said.
“These results are among the most impressive I have seen in this patient population. ISB 2001 has the potential to revolutionize the treatment landscape for heavily pretreated patients with multiple myeloma who have exhausted currently approved therapies,” Hang Quach, M.D., and Professor of Haematology at the University of Melbourne and Director of Haematology at St. Vincent’s Hospital Melbourne was quoted as saying.
T cell activation, proliferation and soluble BCMA reduction were observed in most patients at effective doses, according to Glenmark.
Among the 13 analysts that have coverage on Glenmark Pharma, seven of them have a “buy” recommendation, four said “hold”, while two of them have a “sell” rating.
Shares of Glenmark Pharma are trading 3.3% higher at ₹1,563.7. The stock has risen 82% so far in 2024.
